Incretin Mimetics and Risk of Acute Kidney Injury
We aim to study the possible association between use of incretin mimetics (DPP-4 inhibitors, GLP-1 agonists) and hospitalizations for acute kidney injury. We will answer the following specific questions:
1. Primary outcome: In patients aged 18 years and older, is exposure to GLP-1 based therapies associated with an increased risk of acute kidney injury?
Null Hypothesis 1: There is no association between GLP-1 based therapies and acute kidney injury.
2. Secondary outcome: Is there a difference of risk of acute kidney injury associated with each type of incretin mimetic?
Null Hypothesis 2: There is no difference between GLP-1 agonists or DPP-4 inhibitors in the risk of acute kidney injury.